Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).
Joakim EkstrandChristian FattahMarcus PerssonTony ChengPia NordanskogJonas ÅkesonAnders TingströmMats B LindströmAxel NordenskjöldPouya MovahedPublished in: The international journal of neuropsychopharmacology (2022)
Remission and cumulative symptom reduction following multiple racemic ketamine infusions in severely ill patients (age 18-85 years) in an authentic clinical setting suggest that ketamine, despite being inferior to ECT, can be a safe and valuable tool in treating unipolar depression.
Keyphrases
- end stage renal disease
- open label
- pain management
- depressive symptoms
- clinical trial
- ejection fraction
- phase iii
- chronic kidney disease
- study protocol
- newly diagnosed
- sleep quality
- peritoneal dialysis
- patient reported
- patient reported outcomes
- radiation therapy
- squamous cell carcinoma
- chronic pain
- phase ii study
- ulcerative colitis